Novel Covid vax may provide protection for cancer patients

German researchers have developed a new Covid vaccine that is effective among people with weaker immune systems like cancer patients, particularly those with B-cell deficiencies

Novel Covid vax may provide protection for cancer patients
user

IANS

German researchers have developed a new Covid vaccine that is effective among people with weaker immune systems like cancer patients, particularly those with B-cell deficiencies.

B cells are the immune cells responsible for antibody-mediated responses, which is the main target of all currently approved Covid vaccines. But cancer patients remain immunocompromised as treatments such as chemotherapies and some immunotherapies destroy B cells.

The results presented at the recent AACR Annual Meeting 2022, showed that the vaccine CoVac-1 induced T-cell immune responses in 93 per cent of patients with B-cell deficiencies, including many patients with leukaemia and lymphoma.

To our knowledge, CoVac-1 is currently the only peptide-based vaccine candidate specifically developed and evaluated for immunocompromised patients," said Juliane Walz, Professor at the University Hospital Tubingen in Germany.

The CoVac-1 vaccine enhances the response from T cells - another type of immune cell, and "previous evidence has shown that T cells can combat Covid-19 even in the absence of neutralising antibodies," said Claudia Tandler, a graduate student at the University. "T-cell immune responses against SARS-CoV-2 are of particular importance for patients with B-cell deficiencies, who develop very limited antibody responses after infection or vaccination," Tandler added.

To develop CoVac-1, Tandler and team chose six specific antigens from different parts of the virus (not limited to spike protein as the current vaccines) to make up their vaccine.

CoVac-1 is a peptide vaccine, meaning that the protein pieces are injected directly, rather than being encoded via mRNA.


“CoVac-1-induced T-cell immunity is far more intense and broader, as it is directed to different viral components than mRNA-based or adenoviral vector-based vaccines that are limited to the spike protein and are thus prone to loss of activity due to viral mutations," Tandler said.

In the phase I clinical trial, the researchers recruited 14 patients with a B-cell deficiency, including 12 patients with leukemia or lymphoma. The patients were given a single dose of CoVac-1 and monitored for up to six months for safety and immunogenicity. Notably, 64 per cent of the patients in this study had been previously vaccinated with an approved SARS-CoV-2 vaccine that failed to elicit a humoral immune response.

Fourteen days after vaccination, T-cell immune responses were observed in 71 per cent of patients, which rose to 93 per cent of patients, 28 days after vaccination.

Click here to join our official telegram channel (@nationalherald) and stay updated with the latest headlines